Cadrenal reorganizes portfolio and seeks partnerships
Cadrenal reorganized its clinical portfolio into a Cardiac Acute Critical Care Franchise, shifting focus to late-stage cardiovascular critical care assets.
The company initiated a structured partnering process, targeting out-licensing, portfolio monetization, or co-development deals for CAD-1005, frunexian, and tecarfarin.
Cadrenal said it is pivoting toward a partnership-driven, capital-efficient operating model to accelerate commercialization with larger industry partners.
The company recast the three programs into pre-operative, orphan-pathway, and post-operative pillars; CAD-1005 Phase 2 data showed a greater than 25% absolute thrombotic-event reduction.
CVKD•
